Condition: Ulcerative Colitis · Sponsor: Prometheus Laboratories
The purpose of this study is to determine whether Phosphatidylcholine (LT-02) add on treatment is effective and safe for the induction of remission in ulcerative colitis patients refractory to standard treatment with mesalamine
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Prometheus Site 24 | Phoenix, Arizona, United States | — |
| Prometheus Site 10 | Little Rock, Arkansas, United States | — |
| Prometheus Site 15 | Chula Vista, California, United States | — |
| Prometheus Site 42 | Lancaster, California, United States | — |
| Prometheus Site 30 | Oceanside, California, United States | — |
| Prometheus Site 28 | Rialto, California, United States | — |
| Prometheus Site 2 | Ventura, California, United States | — |
| Prometheus Site 27 | Lafayette, Colorado, United States | — |
| Prometheus Site 45 | Lone Tree, Colorado, United States | — |
| Prometheus Site 35 | Clearwater, Florida, United States | — |
| Prometheus Site 17 | Fort Lauderdale, Florida, United States | — |
| Prometheus Site 55 | Hialeah, Florida, United States | — |
+ 33 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02849951